SALT LAKE CITY, Dec. 31, 2018 /PRNewswire/ -- Lipocine, Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced completion of a definitive phlebotomy study ("Phlebotomy Study") to assess the extent, if any, of clinically meaningful ex vivo conversion of testosterone...
from PR Newswire: https://prn.to/2StjuNH
No comments:
Post a Comment